FrancophonIA/ELRC3.0 huggingface dataset:
English: Malta solution for injection, in a pre-filled pen
Slovenian: Nizozemska raztopina za injiciranje v napolnjeni injekciji (oplossing voor injectie in een voorgevulde) pen
English: 10 mg/1.5 mL solution for injection (oplossing voor injectie )
Slovenian: 10 mg/1,5 ml, solution injectable
English: solution for injection, pre-filled pen
Slovenian: Danska raztopina za injiciranje, napolnjen injekcijski peresnik
English: 15 mg/1.5 mL solution for injection (oplossing voor injectie )
Slovenian: 15 mg/1,5 ml, solution injectable
English: 15 mg/1.5 mL solutrion for injection subcutaneous use
Slovenian: 15 mg/1,5 ml oldatos injekció
English: Norditropin NordiFlex 5 mg/1.5 ml, solution for injection, in pre-filled pen
Slovenian: Norditropin NordiFlex 5 mg/1.5 ml, solution for injection, in prefilled pen
English: Norditropin SimpleXx 5 mg/1.5 ml, solution for injection, in pre-filled pen
Slovenian: Norditropin SimpleXx 5 mg/1.5 ml, solution for injection, in prefilled pen
English: 10 mg/1.5 mL solution for injection in pre-filed pen
Slovenian: 10 mg/1,5 ml, solution injectable en stylo prérempli
English: 15 mg/1.5 mL solution for injection in pre-filed pen
Slovenian: 15 mg/1,5 ml, solution injectable en stylo prérempli
English: Norditropin SimpleXx 10 mg/1,5 ml
Slovenian: Norditropin SimpleXx 10 mg/1,5 mlInjektionslösung
English: • could become pregnant;
Slovenian: • bi lahko zanosile;
English: Evista should not be used in women who:
Slovenian: Zdravila Evista ne smejo uporabljati ženske, ki:
English: The marketing authorisation holder is Daiichi Sankyo Europe GmbH.
Slovenian: Imetnik dovoljenja za promet z zdravilom je družba Daiichi Sankyo Europe GmbH.
English: It is available as white, oval tablets (60 mg).
Slovenian: Na voljo je v belih, ovalnih tabletah (60 mg).
English: The marketing authorisation was renewed on 5 August 2003 and on 5 August 2008.
Slovenian: Dovoljenje za promet z zdravilom je bilo podaljšano 5. avgusta 2003 in 5 avgusta 2008.
English: The recommended dose for adults and the elderly is one tablet taken once a day, with or without food.
Slovenian: Priporočeni odmerek za odrasle in starejše bolnice je ena tableta enkrat dnevno, zaužita s hrano ali brez nje.
English: Other information about Evista:
Slovenian: Druge informacije o zdravilu Evista:
English: If you want more information on the basis of the CHMP recommendations, read the Scientific Discussion (also part of the EPAR).
Slovenian: Če želite več informacij o podlagi za priporočila CHMP, preberite znanstveno razpravo (ki je prav tako del EPAR).
English: The European Commission granted a marketing authorisation valid throughout the European Union for Evista on 5 August 1998.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Evista, veljavno po vsej Evropski uniji, odobrila dne 5. avgusta 1998.
English: What is the risk associated with Evista?
Slovenian: Kakšna tveganja so povezana z zdravilom Evista?
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) EVISTA EPAR summary for the public
Slovenian: EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) EVISTA Povzetek EPAR za javnost
English: The Committee recommended that Evista be given marketing authorisation.
Slovenian: Odbor je priporočil, da se za zdravilo Evista odobri dovoljenje za promet.
English: Evista is a medicine containing the active substance raloxifene hydrochloride.
Slovenian: Evista je zdravilo, ki vsebuje zdravilno učinkovino raloksifenijev hidroklorid.
English: Why has Evista been approved?
Slovenian: Zakaj je bilo zdravilo Evista odobreno?
English: Evista should not be used in people who may be hypersensitive (allergic) to raloxifene or any of the other ingredients.
Slovenian: Zdravila Evista ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) raloksifen ali katero koli drugo sestavino zdravila.
English: What benefit has Evista shown during the studies?
Slovenian: Kakšne koristi je zdravilo Evista izkazalo med študijami?
English: The main measure of effectiveness was how many women had vertebral fractures during the study.
Slovenian: Glavno merilo učinkovitosti je bilo število žensk, ki so med študijo doživele zlom vretenca (hrbtenice).
English: • have liver disease, severe kidney disease, unexplained bleeding from the womb or endometrial cancer (cancer of the lining of the womb).
Slovenian: • imajo obolenje jeter ali hudo obolenje ledvic, nepojasnjene krvavitve iz maternice ali raka endometrija (raka maternične sluznice).
English: Evista has been studied in the treatment and the prevention of osteoporosis in four main studies.
Slovenian: Zdravljenje in preprečevanje osteoporoze z zdravilom Evista je bilo raziskano v štirih glavnih študijah.
English: The most common side effects with Evista (seen in more than 1 patient in 10) are vasodilation (hot flushes) and flu-like symptoms.
Slovenian: Najpogostejši neželeni učinki zdravila Evista (opaženi pri več kot 1 bolnici od 10) so razširitev krvnih žil (navali vročine) in gripi podobni simptomi.
English: Patients may also receive calcium and vitamin D supplements if they do not get enough from their diet. Evista is intended for long-term use.
Slovenian: Bolnice lahko po potrebi jemljejo tudi kalcij in vitamin D, če ju ne dobivajo dovolj s prehrano.
English: Raloxifene has the same effect as oestrogen in the bone, but it does not have an effect in the breast or the womb.
Slovenian: Raloksifen ima enak učinek na kosti kot estrogen, ne učinkuje pa na prsi ali maternico.
English: The Committee for Medicinal Products for Human Use (CHMP) concluded that Evista had shown its effectiveness in preventing and treating osteoporosis, and had no effects on the breast or womb.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je zdravilo Evista izkazalo svojo učinkovitost pri preprečevanju in zdravljenju osteoporoze, na prsi ali maternico pa ni imelo učinka.
English: • have or have had any blood clot disorders, including deep vein thrombosis and pulmonary embolism (a blood clot in the lungs);
Slovenian: • imajo ali so v preteklosti imele težave s krvnimi strdki, vključno s trombozo globokih ven in pljučno embolijo (krvni strdki v pljučih);
English: The active substance in Evista, raloxifene, is a selective oestrogen receptor modulator (SERM).
Slovenian: Zdravilna učinkovina zdravila Evista, raloksifen, je selektivni modulator estrogenskih receptorjev (SERM).
English: Raloxifene acts as an ‘agonist' of the oestrogen receptor (a substance that stimulates the receptor for oestrogen) in some tissues in the body.
Slovenian: Raloksifen deluje kot agonist receptorjev estrogena (snovi, ki stimulira receptorje za estrogen) v nekaterih telesnih tkivih.
English: Over four years, in comparison with placebo, Evista decreased the number of new vertebral fractures by 46% in women who had osteoporosis and by 32% in women who had osteoporosis and an existing fracture.
Slovenian: Med štiriletnim zdravljenjem je zdravilo Evista v primerjavi s placebom zmanjšalo število novih zlomov vretenc za 46 % pri ženskah z osteoporozo in za 32 % pri ženskah z osteoporozo in že obstoječim zlomom kosti.
English: The fourth study compared the effects of Evista with those of placebo in the treatment of osteoporosis in 7,705 women over four years.
Slovenian: Četrta študija je trajala štiri leta, v njej pa so primerjali učinke zdravila Evista z učinki placeba pri zdravljenju osteoporoze pri 7 705 ženskah.
English: Three studies looked at the prevention of osteoporosis in 1,764 women who took either Evista or placebo (a dummy treatment) for two years.
Slovenian: V treh študijah preprečevanja osteoporoze je sodelovalo 1 764 žensk, ki so dve leti jemale bodisi zdravilo Evista ali placebo (zdravilo brez zdravilne učinkovine).
English: Osteoporosis is more common in women after the menopause, when the levels of the female hormone oestrogen fall: oestrogen slows down bone breakdown and makes the bones less likely to fracture.
Slovenian: Osteoporoza je pogostejša pri ženskah v obdobju po menopavzi, ko upade količina ženskega hormona estrogena: ta upočasni razgradnjo kostne mase, zaradi česar je verjetnost zloma manjša.
English: Evista was more effective than placebo in preventing and treating osteoporosis.
Slovenian: Zdravilo Evista je bilo učinkovitejše od placeba pri preprečevanju in zdravljenju osteoporoze.
English: Evista is used for the treatment and prevention of osteoporosis (a disease that makes bones fragile) in women who have been through the menopause.
Slovenian: Zdravilo Evista se uporablja za zdravljenje in preprečevanje osteoporoze (bolezni, ki povzroča krhkost kosti) pri ženskah po menopavzi.
English: For the full list of side effects reported with Evista, see the Package Leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Evista, glejte navodilo za uporabo.
English: Evista has been shown to significantly reduce vertebral fractures (breaks in the spine), but not hip fractures.
Slovenian: Dokazano je bilo, da zdravilo Evista znatno zmanjšuje število zlomov vretenc (poškodb hrbtenice), ne pa tudi zlomov kolka.
English: The studies measured the density of the bones.
Slovenian: V teh študijah so merili kostno gostoto.
English: When used to treat osteoporosis, Evista was more effective than placebo in reducing the number of vertebral fractures.
Slovenian: Ko je bilo zdravilo Evista uporabljeno za zdravljenje osteoporoze, je bilo pri zmanjšanju števila zlomov vretenc učinkovitejše od placeba.
English: Osteoporosis happens when not enough new bone grows to replace the bone that is naturally broken down.
Slovenian: Do osteoporoze pride, ko rast nove kostne mase ni več zadostna, da bi nadomestila njeno naravno razgradnjo.
English: In the prevention of osteoporosis, women receiving Evista had an increase in bone density in the hip or spine of 1.6% over two years, and those receiving placebo had a decrease of 0.8%.
Slovenian: Pri preprečevanju osteoporoze se je pri ženskah, ki so prejemale zdravilo Evista, v dveh letih gostota kosti v kolkih ali hrbtenici povečala za 1,6 %, pri tistih, ki so prejemale placebo, pa se je zmanjšala za
English: What is Evista used for?
Slovenian: Za kaj se zdravilo Evista uporablja?
English: The Committee decided that Evista's benefits are greater than its risks for the treatment and prevention of osteoporosis in postmenopausal women.
Slovenian: Odbor je sklenil, da so koristi zdravila Evista pri zdravljenju in preprečevanju osteoporoze pri ženskah po menopavzi večje od z njim povezanih tveganj.
English: How is Evista used?
Slovenian: Kako se zdravilo Evista uporablja?
English: The full EPAR for Evista is available here.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Evista je na voljo tukaj.
English: How has Evista been studied?
Slovenian: Kako je bilo zdravilo Evista raziskano?
English: What is Evista?
Slovenian: Kaj je zdravilo Evista?
English: There was no effect of Evista on hip fractures.
Slovenian: Na zlome kolkov zdravilo Evista ni imelo učinka.
English: How does Evista work?
Slovenian: Kako zdravilo Evista deluje?
English: Both of these cases were fatal.
Slovenian: Oba ta primera sta bila smrtna.
English: Date of first authorisation: 18 February 2019
Slovenian: Datum prve odobritve: 18. februar 2019
English: The apparent volume of distribution is approximately 155 litres.
Slovenian: Navidezni volumen porazdelitve je približno 155 litrov.
English: It may be taken at any time of the day but it is recommended to be taken at the same time every day.
Slovenian: Lahko se jemlje ob katerem koli času dneva, vendar ga je priporočljivo jemati vsak dan ob istem času.
English: AT, BE, BG, CY, CZ, DK, EE, IE, EL, FI, FR, HR, HU, IE, IS, LT, LU, LV, MT, , NO, PL, PT, RO, SE, SI, SK
Slovenian: AT, BE, BG, CY, CZ, DK, EE, IE, EL, FI, FR, HR, HU, IE, IS, LT, LU, LV, MT, NO, PT, RO, SE, SI, SK
English: Do not take this medicine if any of the above applies to you.
Slovenian: Ne jemljite tega zdravila, če karkoli od zgoraj navedenega velja za vas.
English: - if you have had a heart attack within the last 3 months or if you have other severe problems with your heart which cause daily symptoms
Slovenian: - če ste v zadnjih 3 mesecih doživeli srčni infarkt ali če imate druge hude težave s srcem, ki povzročajo vsakodnevne simptome;
English: - The other ingredients are:
Slovenian: - Druge sestavine zdravila so:
English: Treatment Difference [95% Cl]
Slovenian: razlika zaradi zdravljenja [95 % IZ]
English: This medicine is not for children or adolescents under the age of 18 years because the effects of the medicine in children and adolescents are not known.
Slovenian: To zdravilo ni namenjeno za otroke ali mladostnike, mlajše od 18 let, ker učinki zdravila pri otrocih in mladostnikih niso znani.
English: Hexal AG
Slovenian: DE Hexal AG
English: Prior to enrollment, patients had been using their current opioid for an average of 5 years.
Slovenian: Pred vključitvijo v študijo so bolniki uporabljali svoj trenutni opioid povprečno 5 let.
English: However, once you start taking the medicine, take it at around the same time each day.
Slovenian: Ko pa zdravilo začnete jemati, ga jemljite vsak dan ob približno istem času.
English: Film-coated tablet (tablet).
Slovenian: Filmsko obložena tableta (tableta).
English: There is no clinically significant food effect.
Slovenian: Hrana nima klinično pomembnega učinka.
English: • You can take Rizmoic at any time of the day, with food or between meals.
Slovenian: • Zdravilo Rizmoic lahko jemljete ob katerem koli času dneva, bodisi s hrano ali med obroki.
English: Approximately 20% of the naldemedine dose is excreted unchanged in urine.
Slovenian: Približno 20 % odmerka naldemedina se je izločilo nespremenjenega v urinu.
English: However if it is less than 12 hours until your next dose, skip the missed dose, and wait until it is time to take your next tablet.
Slovenian: Če pa je do vašega naslednjega odmerka manj kot 12 ur, preskočite izpuščeni odmerek in počakajte do takrat, ko bo čas za naslednjo tableto.
English: Age, gender, body weight and race
Slovenian: Starost, spol, telesna masa in rasa
English: The safety and efficacy of naldemedine in children and adolescents aged below 18 years have not yet been established.
Slovenian: Varnosti in učinkovitosti naldemedina pri otrocih in mladostnikih, mlajših od 18 let, še niso dokazali.
English: Not Known (frequency cannot be estimated from the available data)
Slovenian: Neznana (ni mogoče oceniti iz razpoložljivih podatkov):
English: The effects of the medicine in pregnant women are not known.
Slovenian: Učinki zdravila pri nosečnicah niso znani.
English: Patients with OIC
Slovenian: Bolniki z OIC
English: Your doctor will advise you about whether you can use Rizmoic if you are pregnant.
Slovenian: Zdravnik vam bo svetoval, ali lahko jemljete zdravilo Rizmoic, če ste noseči.
English: Pharmacokinetics in subpopulations
Slovenian: Farmakokinetika v podskupinah
English: The studies included a 2-week Screening Period, 2-week Treatment Period and 4-week Follow-up Period.
Slovenian: Študije so vključevale 2-tedensko obdobje presejanja, 2-tedensko obdobje zdravljenja in 4-tedensko obdobje kontroliranja po zdravljenju.
English: A SBM was defined as a bowel movement (BM) without rescue laxative taken within the past 24 hours.
Slovenian: SBM je bilo opredeljeno kot iztrebljanje (bowel movement - BM) brez uporabe rešilnega odvajala v zadnjih 24 urah.
English: 4.5 Interaction with other medicinal products and other forms of interaction
Slovenian: 4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Učinki drugih zdravil na naldemedin
English: The absolute bioavailability of naldemedine is estimated to be in the range of 20% to 56%.
Slovenian: Ocenjujejo, da je absolutna biološka uporabnost naldemedina v mejah od 20 % do 56 %.
English: Opioid withdrawal syndrome typically develops within minutes to several days following administration of an opioid antagonist.
Slovenian: Sindrom odtegnitve opioidov se značilno razvije nekaj minut do več dni po uporabi opioidnega antagonista.
English: It is therefore considered that the presented cases are sufficient to support an update to the product information to both section 4.4 and 4.8.
Slovenian: Mnenje je, da ob upoštevanju teh informacij predstavljeni primeri zadostno podpirajo posodobitev informacij o zdravilu v poglavjih 4.4 in 4.8.
English: • hairs of the skin standing on end
Slovenian: • dlačice na koži se postavijo pokonci,
English: Gastrointestinal perforation is added a new adverse reaction with a frequency “Not known”.
Slovenian: Gastrointestinalna perforacija je dodana kot nov neželeni učinek s pogostnostjo “neznana”.
English: Rizmoic should be taken once daily, with or without food (see section 5.2).
Slovenian: Zdravilo Rizmoic je treba jemati enkrat na dan, s hrano ali brez nje (glejte poglavje 5.2).
English: A QTc study performed with naldemedine in healthy volunteers did not indicate any prolongation of the QT interval.
Slovenian: Študija intervala QTc, opravljena z naldemedinom pri zdravih prostovoljcih, ni pokazala podaljšanja intervala QT.
English: If you miss a tablet of Rizmoic, take it as soon as you remember.
Slovenian: Če ste pozabili vzeti tableto zdravila Rizmoic, jo vzemite takoj, ko se spomnite.
English: Treatment difference
Slovenian: razlika zaradi zdravljenja
English: Whilst the more limited information provided in these five cases is acknowledged the assessor considers that the potential role of Naldemedine cannot be excluded in all of these.
Slovenian: Kljub potrditvi, da so razpoložljivi podatki v teh petih primerih pomanjkljivi, po mnenju ocenjevalca, v nobenem od teh primerov ni mogoče izključiti možne vloge naldemedina.
English: • Gastrointestinal perforation (a hole developing in the bowel wall)
Slovenian: • gastrointestinalna perforacija (v črevesni steni nastane luknja).
English: The overall benefit risk for each patient should be taken into account.
Slovenian: Pri vsakem bolniku je treba upoštevati celotno razmerje koristi in tveganja.
English: - if you are taking certain medicines such as itraconazole to treat fungal infections, or an antibiotic called rifampicin to treat tuberculosis and other infections.
Slovenian: - če jemljete nekatera zdravila, na primer itrakonazol, za zdravljenje glivičnih okužb, ali antibiotik, ki se imenuje rifampicin, za zdravljenje tuberkuloze in drugih okužb.
English: • sweating
Slovenian: • znojenje,
English: (95% CI: 10.8%, 27.0%, p<0.0001*)
Slovenian: (95 % IZ: 10,8 %, 27,0 %, p < 0,0001*)
English: The symptoms resolved.
Slovenian: Simptomi so izzveneli.
English: • diverticulitis (an illness where your gut is inflamed);
Slovenian: • divertikulitis (bolezen, pri kateri je črevo vneto);
English: The efficacy and safety were also assessed in the laxative inadequate responders (LIR) and non-LIR subgroups.
Slovenian: Učinkovitost in varnost so ocenili tudi v podskupinah preiskovancev, ki so se nezadostno odzvali na odvajalo (laxative inadequate responders - LIR) in preiskovancev, ki niso prejemali odvajala (non-LIR).
English: Kingsfordweg 151 1043GR Amsterdam The Netherlands
Slovenian: Kingsfordweg 151 1043GR Amsterdam
English: These patients should be clinically monitored when taking Rizmoic.
Slovenian: Te bolnike je treba med jemanjem zdravila Rizmoic klinično spremljati.
English: Patients responding, n (%) p value* *Statistically significant: p-values based on the Chi-square test.
Slovenian: bolniki, ki so se odzvali na zdravljenje, n (%) vrednost p* *Statistično značilno: vrednosti p na podlagi testa hi kvadrat.
English: - if you have severe diarrhoea or stomach ache, tell your doctor, so that the doctor can monitor you and treat you with rehydration and appropriate medicines if needed.
Slovenian: - če imate hudo drisko ali bolečine v trebuhu, povejte zdravniku, da vas bo zdravnik lahko spremljal in po potrebi zdravil z rehidracijo in ustreznimi zdravili.
English: The package leaflet is updated accordingly.
Slovenian: Navodilo za uporabo je ustrezno posodobljeno.
English: Patients should be advised to report severe, persistent or worsening symptoms to their physician.
Slovenian: Bolnikom je treba svetovati, naj o hudih, trdovratnih ali naraščajočih simptomih poročajo svojemu zdravniku.
English: If you have these conditions and develop opioid withdrawal symptoms (see section 4) or if the opioid medicine no longer controls your pain, contact your doctor immediately.
Slovenian: Če imate katero od teh bolezni in se pri vas razvijejo simptomi odtegnitve opioidov (glejte poglavje 4) ali vam opioidno zdravilo ne obvladuje več bolečine, se takoj posvetujte z zdravnikom;
English: In juvenile toxicity studies in rats, at the same dose levels, exposure in juvenile animals (PND 10) was increased compared to adult animals (2.3 to 7.4-fold).
Slovenian: V študijah juvenilne toksičnosti pri podganah pri enakih ravneh odmerkov je bila izpostavljenost pri juvenilnih živalih (PND 10) v primerjavi z odraslimi živalmi zvečana (za 2,3 do 7,4-krat).
English: - if you suffer from symptoms of opioid withdrawal syndrome (see section 4 Possible side effects) which can develop within minutes to several days after taking a medicine such as Rizmoic.
Slovenian: - če imate simptome sindroma odtegnitve opioidov (glejte poglavje 4 Možni neželeni učinki), ki se lahko razvijejo v času od nekaj minut do več dni po jemanju zdravila, kakršno je zdravilo Rizmoic.
English: Interaction with strong P-gp inhibitors
Slovenian: Interakcije z močnimi inhibitorji P-gp
English: 7 film-coated tablets 10 film-coated tablets 28 film-coated tablets 30 film-coated tablets 84 film-coated tablets 100 film-coated tablets
Slovenian: 7 filmsko obloženih tablet 10 filmsko obloženih tablet 28 filmsko obloženih tablet 30 filmsko obloženih tablet 84 filmsko obloženih tablet 100 filmsko obloženih tablet
English: • The recommended dose is one 200 microgram tablet once daily.
Slovenian: • Priporočeni odmerek je ena 200-mikrogramska tableta enkrat na dan.
English: If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Slovenian: Nosečnost in dojenje Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom, preden vzamete to zdravilo.
English: Therefore, treatment with naldemedine is not expected to alter the pharmacokinetics of co-administered medicines that are substrates of these enzymes and transporters.
Slovenian: Zato ne pričakujemo, da bo zdravljenje z naldemedinom spremenilo farmakokinetiko sočasno uporabljanih zdravil, ki so substrati teh encimov in prenašalcev.
English: • feeling depressed
Slovenian: • občutek potrtosti,
English: (95% CI: 4.8%, 21.3%, p=0.0020*)
Slovenian: (95 % IZ: 4,8 %, 21,3 %, p=0,0020*)
English: In Study V9235, patients on a stable laxative regimen at screening (52.4%) were allowed to continue using that same regimen without change throughout the study duration.
Slovenian: V študiji V9235 je bilo bolnikom na stabilni shemi odvajal ob presejanju (52,4 %) dovoljeno še naprej uporabljati isto shemo brez sprememb ves čas trajanja študije.
English: Pharmacotherapeutic group: Drugs for constipation, peripheral opioid receptor antagonists, ATC code: A06AH05.
Slovenian: Farmakoterapevtska skupina: zdravila proti zaprtju, periferno delujoči antagonisti opioidnih receptorjev, oznaka ATC: A06AH05.
English: contact@shionogi.eu
Slovenian: contattaci@shionogi.eu
English: Due to the limited therapeutic experience in patients 75 years old and older, naldemedine therapy should be initiated with caution in this age group.
Slovenian: Zaradi omejenih terapevtskih izkušenj pri bolnikih, starih 75 let ali več, je treba pri tej starostni skupini zdravljenje z naldemedinom uvajati previdno.
English: Stop taking Rizmoic and contact your doctor if you get a combination of 3 or more of the following symptoms of opioid withdrawal on the same day:
Slovenian: Prenehajte jemati zdravilo Rizmoic in se obrnite na zdravnika, če dobite istega dne kombinacijo 3 ali več od naslednjih simptomov odtegnitve opioidov: